Plus Duchenne’s landmark phase 3 win, a survival boost in glioblastoma, motion sickness momentum at Vanda, and ACIP’s newborn vaccine chaos (Nov 21-Dec 4, 2025).Subscribe to Biotech Blueprint for free at <a href="biotechblueprint.com" target="_blank" rel="noopener noreferer">biotechblueprint.com</a>.

Plus Duchenne’s landmark phase 3 win, a survival boost in glioblastoma, motion sickness momentum at Vanda, and ACIP’s newborn vaccine chaos (Nov 21-Dec 4, 2025). Subscribe to Biotech Blueprint for free at biotechblueprint.com.

Plus Duchenne’s landmark phase 3 win, a survival boost in glioblastoma, motion sickness momentum at Vanda, and ACIP’s newborn vaccine chaos (Nov 21-Dec 4, 2025).Subscribe to Biotech Blueprint for free at <a href="biotechblueprint.com" rel="noopener noreferrer">biotechblueprint.com</a>.

FDA Tightens Vaccine Pathways, Medicare Slashes Drug Prices — This Week in Biotech #80

Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs.

For more content, please subscribe to biotechblueprint.substack.com.

Technology

Connecting with biotech, pharma, and academic professionals to explore the latest in science, startups, market trends, and breakthroughs. For more content, please subscribe to biotechblueprint.substack.com.

Share FDA Tightens Vaccine Pathways, Medicare Slashes Drug Prices — This Week in Biotech #80

Sign up to save your podcasts

FDA Tightens Vaccine Pathways, Medicare Slashes Drug Prices — This Week in Biotech #80

FDA Tightens Vaccine Pathways, Medicare Slashes Drug Prices — This Week in Biotech #80